Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide

被引:0
|
作者
Donato, Vittorio [1 ]
Papaleo, Antonella [1 ]
Castrichino, Annamaria [1 ]
Banelli, Enzo [1 ]
Giangaspero, Felice [2 ]
Salvati, Maurizio [3 ]
Delfini, Roberto [4 ]
机构
[1] Univ Roma La Sapienza, Dept Radiotherapy, I-00152 Rome, Italy
[2] IRCCS Neuromed, Dept Expt Med, Pozzilli, Israel
[3] IRCCS INM Neuromed, Dept Neurosurg, Pozzilli, Israel
[4] Univ Roma La Sapienza, Dept Neurosci & Neurosurg, Rome, Italy
关键词
EGFR; glioblastoma multiforme; Ki67; p53; PDGF; prognostic factor; temozolomide;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims and background: Glioblastoma multiforme is the most common and most malignant primary brain tumor in adults. The current standard of care for glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy plus temozolomide, given concomitantly with and after radiotherapy. This report is a prospective observational study of 43 cases treated in the Department of Radiotherapy, University of Rome La Sapienza, Italy. We examine the relationship between pathologic features and objective response rate in adult patients treated with concomitant radiation plus temozolomide to identify clinical, neuroradiologic, pathologic, and molecular factors with prognostic significance. Methods: Forty-three consecutive patients (24 males and 19 females), ages 15-77 years (median, 57) with newly diagnosed glioblastoma multiforme, were included in this trial between 2002 and 2004 at our department. All patients were treated with surgery (complete resection in 81%, incomplete in 19%) followed by concurrent temozolomide (75 mg/m(2)/day) and radiotherapy (median tumor dose, 60 Gy), followed by temozolomide, 200 mg/m(2)/day for 5 consecutive days every 28 days. Neurologic evaluations were performed monthly and cranial magnetic resonance bimonthly. We analyzed age, clinical manifestations at diagnosis, seizures, Karnofsky performance score, tumor location, extent of resection, proliferation index (Ki-67 expression), p53, platelet-derived growth factor and epidermal growth factor receptor immunohistochemical expression as prognostic factors in the patients. The Kaplan-Meier statistical method and logrank test were used to assess correlation with survival. Results: Fourteen patients (32%) manifested clinical and neuroradiographic evidence of tumor progression within 6 months of surgery. In contrast, 5 patients (12%) showed no disease progression for 18 months from the beginning of treatment. Median overall survival was 19 months. Multivariate analysis revealed that an age of 60 years or older (P <0.03), a postoperative performance score : 70 (P = 0.04), the nontotal tumor resection (P = 0.03), tumor size >4 cm (P = 0.01) and proliferation index overexpression (P = 0.001) were associated with the worst prognosis. p53, PDGF and EGFR overexpression were not significant prognostic factors associated with survival. Conclusions: The results suggest that analysis of prognostic markers in glioblastoma multiforme is complex. In addition to previously recognized prognostic variables such as age and Karnofsky performance score, tumor size, total resection and proliferation index overexpression were identified as predictors of survival in a series of patients with glioblastoma multiforme.
引用
收藏
页码:248 / 256
页数:9
相关论文
共 50 条
  • [1] Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide
    Stupp, R
    Dietrich, PY
    Kraljevic, SO
    Pica, A
    Maillard, I
    Maeder, P
    Meuli, R
    Janzer, R
    Pizzolato, G
    Miralbell, R
    Porchet, F
    Regli, L
    de Tribolet, N
    Mirimanoff, RO
    Leyvraz, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1375 - 1382
  • [2] Selenium in the glioblastoma multiforme treated with concomitant radiotherapy and temozolomide
    Micke, O.
    Bruns, F.
    Muecke, R.
    Buentzel, J.
    Schaefer, U.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 82 - 83
  • [3] Selenium in the glioblastoma multiforme treated with concomitant radiotherapy and temozolomide
    Micke, O.
    Bruns, F.
    Muecke, R.
    Schaefer, U.
    [J]. ONKOLOGIE, 2008, 31 : 75 - 75
  • [4] Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients
    Combs, Stephanie E.
    Wagner, Johanna
    Bischof, Marc
    Welzel, Thomas
    Wagner, Florian
    Debus, Juergen
    Schulz-Ertner, Daniela
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (04): : 987 - 992
  • [5] Outcomes and Prognostic Features of Glioblastoma Multiforme in the Temozolomide Era
    Rowe, L.
    Mackey, M.
    Smart, D. K.
    Ning, H.
    Gilbert, M. R.
    Camphausen, K. A.
    Krauze, A. V.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E100 - E100
  • [6] Radiotherapy with concomitant temozolomide in elderly patients with glioblastoma multiforme
    Gerstein, J.
    Franz, K.
    Eberlein, K.
    Roedel, C.
    [J]. ONKOLOGIE, 2010, 33 : 56 - 56
  • [7] OUTCOME OF PATIENTS WITH GLIOBLASTOMA MULTIFORME ARISING FROM SUBVENTRICULAR ZONE WHO WERE TREATED WITH CONCOMITANT RADIATION AND TEMOZOLOMIDE
    Almubarak, Mohammed
    Torres-Trejo, Alejandro
    Altaha, Ramin
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 818 - 818
  • [8] Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide
    Topkan, Erkan
    Selek, Ugur
    Ozdemir, Yurday
    Yildirim, Berna A.
    Guler, Ozan C.
    Ciner, Fuat
    Mertsoylu, Huseyin
    Tufan, Kadir
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2018, 139 (02) : 411 - 419
  • [9] Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide
    Erkan Topkan
    Ugur Selek
    Yurday Ozdemir
    Berna A. Yildirim
    Ozan C. Guler
    Fuat Ciner
    Huseyin Mertsoylu
    Kadir Tufan
    [J]. Journal of Neuro-Oncology, 2018, 139 : 411 - 419
  • [10] OUTCOME OF CONCOMITANT CHEMORADIATION WITH TEMOZOLOMIDE FOLLOWED BY TEMOZOLOMIDE IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
    Zaki, Adeeba
    [J]. NEURO-ONCOLOGY, 2018, 20 : 200 - 200